TODD SEAMONS: Open Payments
NPI 1821125907 · OREM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$682 in 36 payments from 21 companies in 2025. Trend: 2023 $1,224 · 2024 $1,325 · 2025 $682
Food & beverage: $682
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $159 |
| Axsome Therapeutics, Inc. | 2 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| Abbott Laboratories | 1 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Indivior Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
| Corium, LLC | 1 | $21 |
Products named: QULIPTA, VRAYLAR, Auvelity, FREESTYLE LIBRE 3, CAPLYTA, SPRAVATO, TRINTELLIX, AIRSUPRA.
Industry payments across UT — which companies pay providers there.
